Sugi Predict

Sugi Predict / Compounds / SCHEMBL2496142

SCHEMBL2496142

SCHEMBL2496142

Cn1c(=O)c2c(nc(Cl)n2C)n(C)c1=O

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 3/20 0.61
▸ CYP1A2 P05177 2/20 0.61
▸ RECQL P46063 1/20 0.61
▸ KMT2A Q03164 3/20 0.58
▸ RXFP1 Q9HBX9 2/20 0.58
▸ HTT P42858 1/20 0.55
▸ MAPK1 P28482 1/20 0.53
▸ MAOB P27338 4/20 0.52
▸ MAOA P21397 2/20 0.52
▸ ADORA2A P29274 4/20 0.51
▸ ADORA2B P29275 3/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11226866 0.98 CYP2C19 (0.59) CYP2C19CYP1A2RECQLKMT2ARXFP1
SCHEMBL20561717 0.86 CYP2C19 (0.57) CYP2C19CYP1A2RECQLKMT2ARXFP1
SCHEMBL27887211 0.85 CYP2C19 (0.58) CYP2C19CYP1A2RECQLKMT2ARXFP1
Fluorobenzene SCHEMBL27582843 0.84 ADORA2A (0.57) KMT2ARXFP1HTTMAOBMAOA
SCHEMBL460340 0.80 CYP1A2 (0.75) CYP2C19CYP1A2RECQLHTTMAPK1
SCHEMBL25227669 0.80 ALDH1A1 (0.55) CYP2C19CYP1A2RECQLKMT2AHTT
SCHEMBL2403877 0.79 ADORA2B (0.69) CYP2C19KMT2ARXFP1MAPK1MAOB
SCHEMBL6847258 0.79 CYP2C19 (0.68) CYP2C19CYP1A2RECQLRXFP1HTT
SCHEMBL25219229 0.79 CYP1A2 (0.83) CYP2C19CYP1A2RECQLKMT2ARXFP1
SCHEMBL6847172 0.78 CYP1A2 (0.71) CYP2C19CYP1A2RECQLKMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115572296-B Method for reducing absorbance index of caffeine product 青岛科技大学 2023-11-21 — — CN claimed
CN-115572296-A Method for reducing absorbance index of caffeine product 青岛科技大学 2023-01-06 — — CN claimed
CN-108997350-B Cyclin-dependent kinase 8 inhibitor 南昌立德生物技术有限公司 2021-03-02 — — CN claimed
CN-108997350-A A kind of 8 inhibitor of cyclin-dependent kinase 南昌立德生物技术有限公司 2018-12-14 — — CN claimed
US-20240392273-A1 FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-11-28 — — US disclosed
US-20240327323-A1 Methods of Treating of Halogen- Containing Waste Plastic to Produce Halogenated Products U. S. DEPARTMENT OF ENERGY 2024-10-03 — — US disclosed
EP-3624846-B1 HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY INCLUDING A COMBINATION OF NICOTINIC ACID AND TRYOPTOPHAN BHAMIS RES LABORATORY PVT LTD (IN) 2024-08-07 — — EP disclosed
EP-4401758-A1 FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE Takeda Pharmaceutical Company Limited (JP) 2024-07-24 — — EP disclosed
US-20240115702-A1 HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY Bhami's Research Laboratory, Pvt. Ltd. (IN) 2024-04-11 — — US disclosed
US-11738082-B2 High concentration protein formulations with reduced viscosity Bhami's Research Laboratory, Pvt. Ltd. (IN) 2023-08-29 — — US disclosed
US-11666577-B2 MLKL inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-06-06 — — US disclosed
US-11666577-B2 MLKL inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-06-06 — — US disclosed
US-20040092536-A1 Neurologically active compounds and compounds with multiple activities NAFTCHI N ERIC (US) 2004-05-13 — — US disclosed
US-6413962-B1 ANESTHESIA AND TEMPERATURES REDUCTION; ALPHA-ADRENOCEPTOR AGONIST; RESTORATIVE TO CENTRAL NERVOUS SYSTEM, ESPECIALLY MOTOR AND SENSORY FUNCTIONAL LOSSES FROM TRAMATIC SPINAL CORD INJURIES; ANTISPASTICS; NONSEDATIVE; SIDE EFFECT REDUCTION NAFTCHI N ERIC (US) 2002-07-02 — — US disclosed
US-5958933-A HAVING A GUANIDINO GROUP ALIPHATICALLY LINKED TO A XANTHINE GROUP, ADRENERGIC STIMULANTS NAFTCHI N ERIC (US) 1999-09-28 — — US disclosed
US-5281605-A Pharmaceuticals SANDOZ LTD. (CH) 1994-01-25 — — US disclosed
EP-0258191-B1 XANTHINE DERIVATIVES SANDOZ AG (CH) 1992-05-27 — — EP disclosed
WO-1988005775-A1 NOVEL XANTHINE DERIVATIVES SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. (AT) 1988-08-11 — — WO disclosed
EP-0258191-A1 Xanthine derivatives SANDOZ AG (CH) 1988-03-02 — — EP disclosed
US-4416878-A ANTITUMOR AGENTS KLOSA JOSEF (DE) 1983-11-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11738082-B2 High concentration protein formulations with reduced viscosity ALB, TTR, MAX CYP2C19 4806/4885CYP1A2 4857/4885RECQL 1351/4885
US-20240115702-A1 HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY ALB, TTR, MAX CYP2C19 4806/4885CYP1A2 4857/4885RECQL 1351/4885
US-20040092536-A1 Neurologically active compounds and compounds with multiple activities ACHE, GRIN2A, GRIK2 CYP2C19 2969/4885CYP1A2 2200/4885RECQL 3241/4885
US-20240327323-A1 Methods of Treating of Halogen- Containing Waste Plastic to Produce Halogenated Products VCL, SLC6A12, TPO CYP2C19 776/4885CYP1A2 1429/4885RECQL 1753/4885
US-11666577-B2 MLKL inhibitors MLKL, CMKLR1, PCSK9 CYP2C19 3887/4885CYP1A2 4629/4885RECQL 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.